Operating Income: The income after operating expenses.
CytomX Therapeutics, Inc. (CTMX) had Operating Income of $-22.36M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$76.20M |
|
$-20.37M |
|
-- |
|
$76.20M |
|
$98.56M |
|
|
Operating Income |
$-22.36M |
$5.23M |
|
$-17.13M |
|
$-17.13M |
|
$-17.37M |
|
$-17.37M |
|
$-17.37M |
|
$-17.37M |
|
$-22.36M |
|
$-23.19M |
|
137.94M |
|
137.94M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$143.92M |
|
$1.30M |
|
$7.64M |
|
$151.57M |
|
$46.62M |
|
-- |
|
$5.94M |
|
$52.56M |
|
$99.01M |
|
$97.62M |
|
$99.01M |
|
170.19M |
|
| Cash Flow Statement Financials | |
$-75.59M |
|
$-59.74M |
|
$110.45M |
|
$39.08M |
|
$14.19M |
|
$-24.89M |
|
$6.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-29.35% |
|
-29.35% |
|
-30.44% |
|
-22.48% |
|
-26.73% |
|
$-75.81M |
|
-- |
|
-- |
|
-- |
|
0.50 |
|
-- |
|
37.85 |
|
9.64 |
|
-17.54% |
|
-17.79% |
|
-11.46% |
|
-17.54% |
|
$0.58 |
|
$-0.55 |
|
$-0.55 |
|